 |
|
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(3):326-344. Published online 2024 Apr 26 DOI: https://doi.org/10.3350/cmh.2024.0155
|
|
Citations to this article as recorded by
 Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-ana
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2025; 31(1): 261. CrossRef Integrative analysis of serum proteomics and transcriptomics in hepatitis C
Jianqiong Wang, Andong Xia, Min Tang, Shengjun Yang, Yandi Shen, Jinhua Dao, Rui Tao, Wei Yue
Virology Journal.2025;[Epub] CrossRef High prevalence of antinuclear antibodies in hepatitis C related hepatocellular carcinoma
Mohamed El-Far, Ahmed S. Mustafa, AbdelfattahM. Attallah, Mohamed A. Abdelrazek
Journal of Immunoassay and Immunochemistry.2025; : 1. CrossRef Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatoc
Seren M. Gedallovich, Paul Y. Kwo
Clinical and Molecular Hepatology.2024; 30(4): 677. CrossRef The role of artificial intelligence in the management of liver diseases
Ming‐Ying Lu, Wan‐Long Chuang, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences.2024; 40(11): 962. CrossRef
|